Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Gepotidacin in Pediatric Participants With Bacterial Infection
NCT07371429Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gepotidacin in bacterial infection and urinary tract infection (UTI), sponsored by GSK. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration at 24 hours, Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinite Time at 24 hours and 4 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
gepotidacin
03
Conditions
bacterial infectionurinary tract infection (UTI)
Beyond the preview
Go deeper on NCT07371429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371429.